Intestinal Inflammation: Biologics and Small Molecules
- 1 January 2024
- book chapter
- Published by Springer Nature
- p. 553-574
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosisJoint Bone Spine, 2020
- Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysisClinical Gastroenterology and Hepatology, 2020
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory DisordersClinical Gastroenterology and Hepatology, 2018
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel DiseaseJAMA, 2017
- Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel DiseaseJAMA, 2014
- Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)Journal of Crohn's and Colitis, 2014
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998